News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
720,757 Results
Type
Article (76514)
Company Profile (363)
Press Release (643880)
Section
Business (194100)
Career Advice (3267)
Deals (36054)
Drug Delivery (114)
Drug Development (86208)
Employer Resources (180)
FDA (16707)
Job Trends (15741)
News (343322)
Policy (34950)
Tag
Academia (2969)
Alliances (49528)
Alzheimer's disease (1329)
Approvals (16607)
Artificial intelligence (147)
Bankruptcy (341)
Best Places to Work (12085)
Biotechnology (255)
Breast cancer (125)
Cancer (1112)
Cardiovascular disease (97)
Career advice (2766)
Cell therapy (252)
Clinical research (68006)
Collaboration (391)
Compensation (192)
COVID-19 (2790)
C-suite (98)
Data (1067)
Diabetes (166)
Diagnostics (6430)
Drug pricing (100)
Earnings (71800)
Employer resources (158)
Events (103616)
Executive appointments (294)
FDA (17229)
Funding (349)
Gene therapy (192)
GLP-1 (685)
Government (4881)
Healthcare (20172)
Infectious disease (2880)
Inflammatory bowel disease (119)
Interviews (613)
IPO (16806)
Job creations (4024)
Job search strategy (2292)
Layoffs (481)
Legal (8362)
Lung cancer (183)
Manufacturing (193)
Medical device (13858)
Medtech (13863)
Mergers & acquisitions (19330)
Metabolic disorders (455)
Neuroscience (1616)
NextGen Class of 2024 (7290)
Non-profit (4984)
Northern California (1421)
Obesity (262)
Opinion (242)
Patents (105)
People (57415)
Phase I (20822)
Phase II (29654)
Phase III (22449)
Pipeline (449)
Postmarket research (3202)
Preclinical (9229)
Radiopharmaceuticals (251)
Rare diseases (228)
Real estate (6282)
Regulatory (23099)
Research institute (2606)
Resumes & cover letters (521)
Southern California (1260)
Startups (3910)
United States (13269)
Vaccines (648)
Weight loss (214)
Date
Last 7 days (937)
Last 30 days (3523)
Last 365 days (36724)
2024 (33263)
2023 (41411)
2022 (52634)
2021 (57291)
2020 (56135)
2019 (49977)
2018 (38046)
2017 (35104)
2016 (34562)
2015 (39753)
2014 (32026)
2013 (30864)
2012 (30048)
2011 (30407)
2010 (29075)
Location
Africa (1054)
Arizona (150)
Asia (43437)
Australia (7750)
California (3203)
Canada (1238)
China (249)
Colorado (148)
Connecticut (149)
Europe (101207)
Florida (443)
Georgia (108)
Illinois (371)
Indiana (195)
Kansas (101)
Maryland (583)
Massachusetts (2553)
Michigan (156)
Minnesota (271)
New Jersey (935)
New York (919)
North Carolina (789)
Northern California (1421)
Ohio (137)
Pennsylvania (830)
South America (1401)
Southern California (1260)
Texas (459)
Washington State (362)
720,757 Results for "st louis university".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bio NC
Asensus Surgical Announces St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan to Initiate Senhance Surgery Program
Asensus Surgical, Inc. announced that St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan has entered into an agreement to lease and utilize a Senhance® Surgical System in the Urology and Gastroenterology/General Surgery department.
June 24, 2024
·
5 min read
Job Trends
Thermo Fisher Scientific Expands St. Louis Manufacturing for Complex Biologic Treatments
Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune conditions to rare genetic disorders.
October 5, 2023
·
3 min read
Interventional DiviTum(R) TKa Trial Launches at Washington University
Biovica, active in blood-based cancer monitoring, announces that a clinical trial, BettER, is being launched at Washington University School of Medicine in St. Louis.
March 13, 2024
·
2 min read
Covalon Announces Participation in Oley Conference in St. Louis, Missouri on June 27 – 30, 2023
Covalon Announces Participation in Oley Conference in St. Louis, Missouri on June 27 – 30, 2023.
June 27, 2023
·
7 min read
BioMidwest
The Retina Center of St. Louis County Applauds Data Confirming Dietary Oral Zeaxanthin Decreases the Progression of Wet Age-Related Macular Degeneration
The Retina Center of St. Louis County is excited to share recent data that was published in the peer-reviewed journal Ophthalmology and Therapy, titled Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost-Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration.
September 12, 2023
·
3 min read
Press Releases
CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to Stelara®
October 21, 2024
·
2 min read
Business
Seismic Therapeutic Appoints Brendan St. Amant as General Counsel
Seismic Therapeutic, Inc today announced the appointment of Brendan St. Amant as General Counsel and a member of the company’s leadership team.
June 25, 2024
·
2 min read
Business
Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101
Sensei Biotherapeutics, Inc. today announced it has entered into a Sponsored Research Agreement with Washington University in St. Louis, MO, to support development of SNS-101, a conditionally active VISTA-blocking antibody.
November 21, 2022
·
5 min read
FDA
US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®
October 11, 2024
·
1 min read
Business
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
Tharimmune, Inc. announced today an option agreement for an exclusive license with Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2.
April 23, 2024
·
5 min read
1 of 72,076
Next
